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ABSTRACT: The morpholine and piperazine with their
remarkable physical and biochemical properties are popular
heterocycles in organic and medicinal chemistry used in
rational property design. However, in the majority of cases
these rings are added to an existing molecule in a building
block approach thus limiting their substitution pattern and
diversity. Here we introduce a versatile de novo synthesis of
the morpholine and piperazine rings using multicomponent reaction chemistry. The large scale amenable building blocks can be
further substituted at up to four positions, making this a very versatile scaffold synthesis strategy. Our methods thus fulfill the
increasing demand for novel building block design and nontraditional scaffolds which previously were not accessible
Morpholine and piperazines are privileged backbones andare abundantly used as substituents or scaffolds in drugs
and medicinal chemistry.1 They can improve pharmacokinetic
(PK) properties of molecules, such as water solubility and
metabolic stability, while not being essential for direct receptor
binding. They can be introduced by two different general
strategies. Often they are attached via a building block approach
to the receptor binding motif (Figure 1, Imatinib). Less often
they are built de novo and used as a central scaffold thus merging
major receptor binding features with beneficial PK properties. An
elegant de novo assembly of these structures is Bode’s SnAP
strategy.2 AMG-8735 is another example of the latter approach;
however, it is de novo assembled via an overall lengthy multistep
synthesis (∼20 steps).3 In accordance with the above discussion,
it shows major improved properties over the piperidine analogue
such as higher metabolic stability in hepatocytes, as well as good
pharmacokinetic properties. Clearly a de novo approach has
many advantages of the sequential approach, including maximal
control over the substitution pattern and improved ligand
efficiency. However, often the de novo approach is performed via
sequential synthesis and can be time and resource costly. In
general, poor commercial availability of substituted morpho-
lines/piperazines and a paucity of methods for their preparation
can be observed. Therefore, we would like to report an
unprecedented, fast, diverse, and useful multicomponent
reaction (MCR) for de novo assembly of piperazine and
morpolines.4
In order to allow for the fast and diverse assembly of
piperazines and morpholines we envisioned a multicomponent
Ugi approach followed by a cyclization by an intramolecular SN2
reaction. Here we focus on the tetrazole Ugi reaction which in
this context delivers a secondary amine moiety as part of the
morpholine/piperazine design. Due to the superior functional
group compatibility of MCR in principle, different designs are
possible (Scheme 1): one where the oxo component delivers the
nucleofuge and one based on the amine component.
Initially, we envisioned that using an α-halo oxo-component
together with an isocyanide, trimethylsilyl azide, and 2-hydroxy
or 2-amino or 2-mercaptoethylamine and its derivatives will yield
the corresponding Ugi-tetrazole adduct, which under basic
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Figure 1. Examples of bioactive compounds with piperazine and
morpholine moieties and two complementary synthesis strategies.
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conditions should give the corresponding morpholine, piper-
azine, or thiomorpholine respectively (Scheme 2A).
To test this strategy, we decided to use 2-chloroacetaldehyde
as an electrophile and p-chlorobenzyl isocyanide, trimethylsilyl
azide, and ethanolamine as a nucleophile, each 1 equiv, in
methanol stirred for 18 h at room temperature (see Scheme 2A).
We observed the Ugi-adduct formation (4), which was further in
situ treated with various bases to give the corresponding
morpholine derivative (6); however, we only observed trace
product formation. Next, we decided to change the electrophile
and nucleophile positions from the oxo-component and from the
amine component respectively (see Scheme 2B). Unfortunately,
in these in situ methods we were unable to isolate the pure
products (6). However, after isolating the intermediates 4 and 5,
we optimized cyclization conditions with respect to solvents,
bases, temperature, and time (Table 1).
We observed that sodium hydride (85% yields) and tert-BuOK
(79%) in acetonitrile were the optimal base choices for the
cyclization. With these optimized conditions, we isolated the
intermediate of 4 and 5 and treated with sodium hydride (1.5
eqiuv) in acetonitrile for 1 h at 0 °C to obtain the final cyclized
product (6). The Ugi adducts 4a (36%) and 5a (63%) thus give
the morpholine derivative 6a in 45% and 85% respectively. With
these results, we confirmed that the use of an α-hydroxy oxo-
component was higher yielding than that of the α-halo oxo-
component. Also, we tested various isocyanides in the Ugi
reaction followed by the cyclization. In general, we observed
good to excellent yields in both reactions (Table 2).
To further simplify the synthesis, we decided to reinvestigate a
one-pot Ugi-cyclization procedure. We decided to remove the
Ugi solvent methanol after formation of 5a, followed by addition
of NaH in acetonitrile at 0 °C for 1 h. Surprisingly, we obtained
the morpholine derivatives (6a) in an acceptable 50% yield. To
further improve the isolation, we filtered the intermediate (5a)
through a short silica bed and cyclized using 1.5 equiv of NaH in
acetonitrile to give a morpholine derivative (6a), now in 68%
yield. With these optimized conditions, we tested various
isocyanides and hydoxyketones and found in general moderate
to good yields of 3,3-disubstituted morpholines (Table 2).
Scheme 1. Retrosynthetic Design of de Novo Assembly of
Morpholines and Piperazines by an MCR Approach
Scheme 2. MCR Morpholine or Piperazine Synthesis from A
α-Halo Oxo-Component and B α-Hydroxy Oxo-Component
Table 1. Optimization of Cyclization of Ugi-Adduct to
Morpholine
base equiv temp; time solvent % yield of 6aa
Et3N 2 23 °C, 18 h CH2Cl2 −
Et3N 2 23 °C, 5 h CH3CN −
DIPEA 2 23 °C, 18 h CH3CN −
DBU 2 0−23 °C, 18 h CH3CN −
K2CO3 2 23 °C, 18 h CH3CN −
K2CO3 2 23 °C, 18 h CH3CN 27
KOH 2 23 °C, 18 h CH3CN 72
NaOMe 1. 0−23 °C, 18 h CH3CN 51
t-BuOK 3 0−23 °C, 1 h CH3CN 79
NaH 1.5 0 °C, 1 h CH3CN 85
NaH 2 0−23 °C, 5 h CH3CN 30
aIsolated yields.
Table 2. MCR for the Ugi-Adduct 4 and 5 and Synthesis of
Morpholines 6 Derivativesa,b,c
aYields of isolated, analytically pure compounds after chromatography
are given. bThe reactions were performed on 1.0 mmol scale using
amine (1.0 equiv), aldehyde/ketone (1.0 equiv), isocyanide (1.0
equiv), and NaN3 (1.0 equiv) in MeOH (1.0 M); cyclization reaction
was performed in CH3CN using NaH (1.5 equiv) at 0 °C to rt for 1 h.
cOne-pot overall isolated yield.
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Next, we tested the synthesis of piperazine derivatives first
using unsubstituted ethylene diamine. Isolation issues (high
water solubility of the Ugi product) and several side products led
us to use monoboc-protected ethylene diamine (8) instead
(Table 3). For example, monoboc-protected ethylenediamine
reacted with 2-chloroacetaldehyde, benzyl isocyanide, and
trimethylsilyl azide in methanol furnishing the Ugi-tetrazole
adduct 9a in a good 71% isolated yield within 12 h. The isolated
Ugi-adduct 9a was treated with 3 equiv of trifluoroacetic acid
(TFA) in dichloromethane at room temperature for 2 h
furnishing the TFA salt of the amine. After removal of the
solvent, cyclization was accomplished with tBuOK (3 equiv) in
acetonitrile at 60 °C for 1 h, yielding piperazine derivative 10a in
66% overall yield. Different substituted isocyanides in general
gave derivatives (10) in good yields (Table-3, 10b−10e)
including super bulky adamantane isocyanide (10e, 38%).
Next, we explored the use of o-phenylenediamine for the
synthesis of 2-substituted tetrahydroquinoxaline. Analogously,
the monoboc-protected o-phenylenediamine reacted to affod the
Ugi tetrazole product 9f (72% yield), which after deprotection
and base (NaH) induced cyclization yields the quinoxaline 10f
(52%). Moreover, other isocyanides such as benzylisocyanide, 4-
chlorobenzyl isocyanide, and linear and branched aliphatic
isocyanides also reacted with monoboc-protected o-phenyl-
enediamine, chloroacetaldehyde, and trimethylsilyl azide afford-
ing 10g−10l in good yields (Table 3).
Furthermore, to underscore the usefulness of the produced
scaffolds we showcase some further transformations of the
secondary amine of morpholines and piperazines via reductive
amination (11, 72%), sulfonation (12, 72%), acylation (15,
54%), and urea (13, 39%) and thiourea (14, 16, 61%, 33%)
formation (Scheme 3).
Several crystal structures also have been obtained and support
the proposed structures of the scaffolds (Figure 2).
Morpholines and piperazines are among the 25 most frequent
nitrogen heterocycles in U.S. FDA approved drugs.5 From a
medicinal chemistry design standpoint of view, morpholines and
piperazines are outstanding since they combine three-dimen-
sionality with superior PK properties. “Escape from flatland”, i.e.
saturation, correlates well with solubility, an experimental
physical property important to success in the drug discovery
setting.6 Based on the excellent scaffold properties these scaffolds
are now part of the screening decks of the European Lead Factory
(ELF).7−12 In summary, we have identified a novel method for
the synthesis of substituted N-unprotected piperazines, morpho-
lines, and tetrahydroquinoxalines. This robust and operationally
simple two-step, air- and moisture-tolerant procedure is a
valuable addition to MCR chemistry and expands its unique
scaffold diversity. Work is ongoing to identify valuable biological




The Supporting Information is available free of charge on the
ACS Publications website at DOI: 10.1021/acs.orglett.6b03807.
General experimental procedures, compound character-
ization data, 1H and 13C spectra of all compounds (PDF)
Crystallographic data for 6a (CIF)
Table 3. MCR for the Ugi-Adduct of 9 for Piperazine and
Tetrahydroquinoxalines 10 Synthesisa,b,c
aMethod A: cyclization reaction was performed in CH3CN using
tBuOK (3.0 equiv) at 60 °C. bMethod B: cyclization reaction was
performed in CH3CN using NaH (1.5 equiv) at 0 °C to rt for 1 h.
cYields of isolated, analytically pure compounds after chromatography
are given. The reactions were performed on 1.0 mmol scale using
monobocprotected amine (8, 1.0 equiv), α-halo aldehyde/ketone (1.0
equiv), isocyanides (1.0 equiv), and TMSN3 (1.0 equiv) in MeOH
(1.0 M); Boc-deprotection was performed in CH2Cl2 with TFA at rt.
Scheme 3. Further Functionalization of Morpholines and
Piperazines
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Crystallographic data for 6f (CIF)
Crystallographic data for 6j (CIF)
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